<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Freedom-to-Operate Analysis: MUPS Formulation vs. Veradermics Patent US12268688B2</title>
    <style>
        body {
            font-family: 'Arial', sans-serif;
            line-height: 1.6;
            max-width: 950px;
            margin: 0 auto;
            padding: 40px 20px;
            color: #333;
        }
        h1 {
            color: #c5221f;
            border-bottom: 3px solid #c5221f;
            padding-bottom: 10px;
        }
        h2 {
            color: #185abc;
            margin-top: 40px;
            border-bottom: 1px solid #ddd;
            padding-bottom: 5px;
        }
        h3 {
            color: #1967d2;
            margin-top: 25px;
        }
        h4 {
            color: #444;
            margin-top: 20px;
        }
        table {
            border-collapse: collapse;
            width: 100%;
            margin: 15px 0;
        }
        th, td {
            border: 1px solid #ddd;
            padding: 10px 12px;
            text-align: left;
            vertical-align: top;
        }
        th {
            background-color: #f8f9fa;
            font-weight: bold;
            color: #185abc;
        }
        tr:nth-child(even) {
            background-color: #f8f9fa;
        }
        .warning-box {
            background-color: #fce8e6;
            padding: 15px;
            border-left: 4px solid #d93025;
            margin: 20px 0;
        }
        .success-box {
            background-color: #e6f4ea;
            padding: 15px;
            border-left: 4px solid #34a853;
            margin: 20px 0;
        }
        .info-box {
            background-color: #e8f0fe;
            padding: 15px;
            border-left: 4px solid #1a73e8;
            margin: 20px 0;
        }
        .caution-box {
            background-color: #fff3cd;
            padding: 15px;
            border-left: 4px solid #ffc107;
            margin: 20px 0;
        }
        .claim-box {
            background-color: #f5f5f5;
            padding: 15px;
            border: 1px solid #ddd;
            margin: 15px 0;
            font-family: 'Courier New', monospace;
            font-size: 13px;
        }
        hr {
            border: none;
            border-top: 1px solid #ddd;
            margin: 30px 0;
        }
        .risk-high { color: #c5221f; font-weight: bold; }
        .risk-medium { color: #b45309; font-weight: bold; }
        .risk-low { color: #137333; font-weight: bold; }
        ul, ol { margin: 10px 0; padding-left: 25px; }
        li { margin: 5px 0; }
    </style>
</head>
<body>

<h1>Freedom-to-Operate Analysis</h1>
<h2 style="border: none; margin-top: 10px;">MUPS Formulation vs. Veradermics Patent US12268688B2</h2>
<p><strong>Date:</strong> February 5, 2026</p>
<p><strong>Subject:</strong> Multi-Particulate Pellet System (MUPS) Extended-Release Minoxidil 8.5mg</p>
<p><strong>Patent:</strong> US 12,268,688 B2 (Issued April 8, 2025)</p>
<p><strong>Patent Holder:</strong> Veradermics, Inc.</p>

<div class="warning-box">
    <strong>DISCLAIMER:</strong> This analysis is for informational purposes only and does not constitute legal advice. A qualified patent attorney should review this analysis and conduct formal freedom-to-operate due diligence before commercialization.
</div>

<hr>

<h2>Executive Summary</h2>

<table>
    <tr>
        <th>Assessment Category</th>
        <th>Risk Level</th>
        <th>Summary</th>
    </tr>
    <tr>
        <td><strong>Literal Infringement</strong></td>
        <td class="risk-medium">MEDIUM RISK</td>
        <td>Claims are broadly written as METHOD claims covering any "modified release" formulation achieving specified PK parameters. MUPS could literally meet claim elements if PK targets overlap.</td>
    </tr>
    <tr>
        <td><strong>Doctrine of Equivalents</strong></td>
        <td class="risk-medium">MEDIUM RISK</td>
        <td>Ethylcellulose performs a similar function (sustained release) but via a different mechanism (membrane diffusion vs. gel erosion). Could be argued as equivalent.</td>
    </tr>
    <tr>
        <td><strong>Design-Around Viability</strong></td>
        <td class="risk-low">LOW RISK</td>
        <td>Strong arguments exist for non-infringement based on dosage form (capsule vs. tablet), mechanism (diffusion vs. erosion), and polymer system (ethylcellulose vs. HPMC).</td>
    </tr>
    <tr>
        <td><strong>Overall FTO Assessment</strong></td>
        <td class="risk-medium">MEDIUM RISK - PROCEED WITH CAUTION</td>
        <td>Recommend PK profile differentiation strategy and formal patent attorney review before commercialization.</td>
    </tr>
</table>

<hr>

<h2>Section 1: Patent Claims Analysis</h2>

<h3>1.1 Independent Claims (Key Claims)</h3>

<h4>Claim 1 (Broadest Independent Claim)</h4>
<div class="claim-box">
<strong>Claim 1:</strong> A method of treating hair loss, comprising orally administering to a subject in need thereof a <u>modified release pharmaceutical formulation</u> comprising from about 3.5 mg to about 20 mg of minoxidil or a pharmaceutically acceptable salt thereof; wherein the modified release pharmaceutical formulation provides:<br><br>
&nbsp;&nbsp;(a) a blood level of the minoxidil of about 1 ng/ml to about 20 ng/ml;<br>
&nbsp;&nbsp;(b) a Cmax of about 0.25 ng/ml to about 20 ng/ml; and<br>
&nbsp;&nbsp;(c) a Tmax of about 30 to about 360 minutes.
</div>

<h4>Claim 14 (4.5mg Specific)</h4>
<div class="claim-box">
<strong>Claim 14:</strong> Same structure as Claim 1, but specifically covering about 4.5 mg minoxidil.
</div>

<h4>Claim 18 (9mg Specific)</h4>
<div class="claim-box">
<strong>Claim 18:</strong> Same structure as Claim 1, but specifically covering about 9 mg minoxidil.
</div>

<h4>Claim 24 (Daily Dose Method)</h4>
<div class="claim-box">
<strong>Claim 24:</strong> A method of treating hair loss, comprising orally administering to a subject in need thereof a daily dose of minoxidil from about 3.5 mg to about 20 mg; and the oral administration provides the same PK parameters as Claim 1.
</div>

<h3>1.2 Key Dependent Claims</h3>

<h4>Claim 2 (Release Modifier)</h4>
<div class="claim-box">
<strong>Claim 2:</strong> The method of claim 1, wherein the modified release pharmaceutical formulation further comprises a <u>release modifier</u>, a filler, a glidant, a lubricant, and combinations thereof.
</div>

<h4>Claim 12 (Release Modifier Amount)</h4>
<div class="claim-box">
<strong>Claim 12:</strong> The method of claim 2, wherein the <u>release modifier is present in an amount of about 50% to about 80% (w/w)</u> of the total formulation.
</div>

<div class="caution-box">
    <strong>CRITICAL OBSERVATION:</strong> The claims do NOT specifically mention HPMC, ethylcellulose, or any particular polymer. They broadly claim any "modified release pharmaceutical formulation" with "release modifier" achieving the specified PK parameters. This is broader than expected and increases infringement risk.
</div>

<hr>

<h2>Section 2: Element-by-Element Claim Comparison</h2>

<h3>2.1 Claim 1 Analysis (Broadest Claim)</h3>

<table>
    <tr>
        <th>Claim Element</th>
        <th>Patent Requirement</th>
        <th>Our MUPS Formulation</th>
        <th>Infringement Risk</th>
    </tr>
    <tr>
        <td><strong>"A method of treating hair loss"</strong></td>
        <td>Method claim for hair loss treatment</td>
        <td>Our intended use is hair loss treatment</td>
        <td class="risk-high">HIGH - Same intended use</td>
    </tr>
    <tr>
        <td><strong>"orally administering"</strong></td>
        <td>Oral administration route</td>
        <td>MUPS capsule is orally administered</td>
        <td class="risk-high">HIGH - Same route</td>
    </tr>
    <tr>
        <td><strong>"modified release pharmaceutical formulation"</strong></td>
        <td>Any modified/extended release formulation</td>
        <td>MUPS is an extended release formulation</td>
        <td class="risk-high">HIGH - Meets definition</td>
    </tr>
    <tr>
        <td><strong>"from about 3.5 mg to about 20 mg of minoxidil"</strong></td>
        <td>Dose range 3.5-20mg</td>
        <td>Our dose: 8.5mg (within range)</td>
        <td class="risk-high">HIGH - Within claimed range</td>
    </tr>
    <tr>
        <td><strong>"blood level of about 1 ng/ml to about 20 ng/ml"</strong></td>
        <td>Steady-state blood level</td>
        <td>Expected: ~5-15 ng/mL (within range)</td>
        <td class="risk-high">HIGH - Likely within range</td>
    </tr>
    <tr>
        <td><strong>"Cmax of about 0.25 ng/ml to about 20 ng/ml"</strong></td>
        <td>Peak concentration</td>
        <td>Expected Cmax: ~12-18 ng/mL (within range)</td>
        <td class="risk-high">HIGH - Likely within range</td>
    </tr>
    <tr>
        <td><strong>"Tmax of about 30 to about 360 minutes"</strong></td>
        <td>Time to peak: 0.5-6 hours</td>
        <td>Expected Tmax: 2-5 hours (within range)</td>
        <td class="risk-high">HIGH - Likely within range</td>
    </tr>
</table>

<div class="warning-box">
    <strong>INITIAL ASSESSMENT - CLAIM 1:</strong> If our MUPS formulation achieves the claimed PK parameters (which it likely would to be therapeutically effective), it may literally infringe Claim 1. The claims are written as METHOD claims, not composition claims, and cover ANY modified release formulation achieving the specified PK profile.
</div>

<h3>2.2 Claim 2 & 12 Analysis (Release Modifier Claims)</h3>

<table>
    <tr>
        <th>Claim Element</th>
        <th>Patent Requirement</th>
        <th>Our MUPS Formulation</th>
        <th>Analysis</th>
    </tr>
    <tr>
        <td><strong>"release modifier"</strong></td>
        <td>Generic term - not defined to specific polymer</td>
        <td>Ethylcellulose (Surelease) + Eudragit RS 30D</td>
        <td class="risk-medium">MEDIUM - Ethylcellulose could be considered a "release modifier"</td>
    </tr>
    <tr>
        <td><strong>"50% to about 80% (w/w)"</strong></td>
        <td>Release modifier amount</td>
        <td>Our coating: 15-20% weight gain on pellets; total ethylcellulose ~20-25% of formulation</td>
        <td class="risk-low">LOW - Below claimed range</td>
    </tr>
    <tr>
        <td><strong>"filler"</strong></td>
        <td>Present in formulation</td>
        <td>Sugar spheres (inert core)</td>
        <td class="risk-high">HIGH - Present</td>
    </tr>
    <tr>
        <td><strong>"glidant"</strong></td>
        <td>Present in formulation</td>
        <td>Talc (anti-tacking agent)</td>
        <td class="risk-high">HIGH - Present</td>
    </tr>
    <tr>
        <td><strong>"lubricant"</strong></td>
        <td>Present in formulation</td>
        <td>Not explicitly in our formula</td>
        <td class="risk-low">LOW - May not meet element</td>
    </tr>
</table>

<hr>

<h2>Section 3: Non-Infringement Arguments</h2>

<h3>3.1 Specification Limitation Arguments</h3>

<div class="success-box">
    <strong>Argument 1: Specification Defines "Release Modifier" as HPMC</strong><br><br>
    While the claims use the generic term "release modifier," the specification consistently describes HPMC as the release modifier:
    <ul>
        <li>Table 8 (Patent Examples): All prototypes use HPMC K4M or HPMC K200M as the release modifier</li>
        <li>Prototype A: HPMC K200M 120mg (80% w/w)</li>
        <li>Prototype B: HPMC K4M 45mg (30% w/w)</li>
        <li>Prototype C: HPMC K4M 30mg (20% w/w)</li>
        <li>Prototype D: HPMC K200M 105mg (70% w/w)</li>
    </ul>
    <strong>Legal Principle:</strong> Under claim construction principles, claims should be interpreted in light of the specification. A court may limit "release modifier" to HPMC grades described in the examples.
</div>

<div class="success-box">
    <strong>Argument 2: Different Dosage Form</strong><br><br>
    <table>
        <tr>
            <th>Veradermics</th>
            <th>Our MUPS</th>
        </tr>
        <tr>
            <td>Monolithic matrix TABLET</td>
            <td>Multi-particulate CAPSULE with coated pellets</td>
        </tr>
        <tr>
            <td>Single unit dosage form</td>
            <td>Multiple unit dosage form (many pellets)</td>
        </tr>
        <tr>
            <td>Drug dispersed in matrix</td>
            <td>Drug layered on cores, surrounded by coating</td>
        </tr>
    </table>
    The specification and all examples describe TABLETS. Our capsule-based multi-particulate system is a fundamentally different dosage form architecture.
</div>

<div class="success-box">
    <strong>Argument 3: Different Release Mechanism</strong><br><br>
    <table>
        <tr>
            <th>Veradermics HPMC Matrix</th>
            <th>Our Ethylcellulose Coating</th>
        </tr>
        <tr>
            <td>Hydrophilic gel formation upon hydration</td>
            <td>Hydrophobic membrane remains intact</td>
        </tr>
        <tr>
            <td>Drug release via gel diffusion AND erosion</td>
            <td>Drug release via membrane diffusion ONLY</td>
        </tr>
        <tr>
            <td>Matrix swells and erodes over time</td>
            <td>Coating maintains structural integrity</td>
        </tr>
        <tr>
            <td>pH-dependent (HPMC gel formation affected by pH)</td>
            <td>pH-independent (ethylcellulose insoluble at all GI pH)</td>
        </tr>
    </table>
    <strong>Key Distinction:</strong> The release MECHANISM is fundamentally different even if the release RATE is similar.
</div>

<h3>3.2 Prosecution History Estoppel</h3>

<div class="info-box">
    <strong>Recommended Investigation:</strong> Review the prosecution history (file wrapper) for US12268688B2 to identify:
    <ul>
        <li>Any claim amendments narrowing scope</li>
        <li>Arguments made to distinguish prior art</li>
        <li>Statements limiting the invention to HPMC matrices</li>
    </ul>
    If Veradermics argued during prosecution that their invention was specific to HPMC or matrix tablets, they may be estopped from asserting the claims against non-HPMC or non-matrix formulations.
</div>

<hr>

<h2>Section 4: Patent Invalidity Defense</h2>

<div class="success-box">
    <h3>CRITICAL: Claimed PK Parameters Overlap with Immediate-Release Minoxidil</h3>
    <p>The patent claims may be <strong>INVALID</strong> because standard immediate-release minoxidil already achieves the claimed PK parameters.</p>
</div>

<h3>4.1 The Invalidity Argument</h3>

<table>
    <tr>
        <th>Parameter</th>
        <th>IR Minoxidil 2.5mg (Published)</th>
        <th>Veradermics Claimed Range</th>
        <th>Overlap?</th>
    </tr>
    <tr>
        <td><strong>Cmax</strong></td>
        <td>16.8 ± 7.83 ng/mL</td>
        <td>0.25 - 20 ng/mL</td>
        <td class="risk-high">YES - Falls within range</td>
    </tr>
    <tr>
        <td><strong>Tmax</strong></td>
        <td>1 hour (60 min)</td>
        <td>30 - 360 minutes</td>
        <td class="risk-high">YES - Falls within range</td>
    </tr>
</table>

<p><strong>Source:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/2715373/">Fleishaker et al., J Clin Pharmacol 1989</a>; <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10806356/">PMC10806356</a></p>

<h3>4.2 Potential Invalidity Grounds</h3>

<table>
    <tr>
        <th>Ground</th>
        <th>Statute</th>
        <th>Argument</th>
    </tr>
    <tr>
        <td><strong>Anticipation</strong></td>
        <td>35 U.S.C. §102</td>
        <td>Off-label use of IR minoxidil for hair loss pre-dates the patent priority date (Oct 2022). IR minoxidil achieves the claimed PK parameters. Therefore, the claims are anticipated.</td>
    </tr>
    <tr>
        <td><strong>Obviousness</strong></td>
        <td>35 U.S.C. §103</td>
        <td>It was obvious to administer minoxidil at doses achieving these PK parameters for hair loss, given extensive published literature on off-label use.</td>
    </tr>
    <tr>
        <td><strong>Indefiniteness</strong></td>
        <td>35 U.S.C. §112</td>
        <td>Claims are so broad they cover existing IR minoxidil products, suggesting they don't "particularly point out and distinctly claim" the invention.</td>
    </tr>
</table>

<h3>4.3 Strategic Value of Invalidity Defense</h3>

<div class="info-box">
    <p>Even if our MUPS formulation literally meets the claim elements, we have a strong <strong>invalidity defense</strong> that can be raised in litigation or used to negotiate a favorable settlement.</p>
    <br>
    <p><strong>Recommended Actions:</strong></p>
    <ul>
        <li>Conduct prior art search for oral minoxidil hair loss publications pre-October 2022</li>
        <li>Consider filing Inter Partes Review (IPR) to challenge claims at USPTO</li>
        <li>Use invalidity arguments as leverage in any licensing negotiations</li>
    </ul>
</div>

<hr>

<h2>Section 5: Risk Mitigation Strategies</h2>

<h3>4.1 PK Profile Differentiation (Recommended)</h3>

<div class="caution-box">
    <strong>STRATEGY:</strong> Design the MUPS formulation to achieve a PK profile OUTSIDE the claimed parameters.
    <br><br>
    <table>
        <tr>
            <th>Parameter</th>
            <th>Claimed Range</th>
            <th>Design Target</th>
        </tr>
        <tr>
            <td>Tmax</td>
            <td>30-360 minutes (0.5-6 hours)</td>
            <td><strong>Target Tmax > 6 hours</strong> (e.g., 7-8 hours) to fall outside claim</td>
        </tr>
        <tr>
            <td>Cmax</td>
            <td>0.25-20 ng/mL</td>
            <td>Harder to design around - most therapeutic levels fall within this range</td>
        </tr>
    </table>
    <br>
    <strong>Implementation:</strong> Increase ethylcellulose coating thickness (25-30% weight gain) to delay Tmax beyond 6 hours. This would place the formulation outside Claim 1's Tmax limitation.
</div>

<h3>4.2 Release Modifier Percentage Strategy</h3>

<div class="success-box">
    <strong>STRATEGY:</strong> Ensure release modifier (ethylcellulose) is below 50% w/w to avoid Claim 12.
    <br><br>
    Our current MUPS formulation has ethylcellulose at approximately 20-25% of total capsule fill weight, which is BELOW the 50-80% range in Claim 12. This provides a strong non-infringement argument for the dependent claims.
</div>

<h3>4.3 Indication Carve-Out (Not Recommended)</h3>

<div class="warning-box">
    <strong>NOT RECOMMENDED:</strong> Labeling for a different indication (e.g., hypertension) to avoid "treating hair loss" claim element.
    <br><br>
    <strong>Problems:</strong>
    <ul>
        <li>Induced infringement liability if doctors prescribe off-label for hair loss</li>
        <li>Limits commercial opportunity</li>
        <li>Does not address inevitable off-label use</li>
    </ul>
</div>

<hr>

<h2>Section 5: Detailed Risk Assessment</h2>

<h3>5.1 Infringement Scenarios</h3>

<table>
    <tr>
        <th>Scenario</th>
        <th>Risk Level</th>
        <th>Explanation</th>
    </tr>
    <tr>
        <td><strong>Direct Infringement (35 U.S.C. § 271(a))</strong></td>
        <td class="risk-medium">MEDIUM</td>
        <td>We would not directly infringe by manufacturing/selling - the claims are METHOD claims requiring administration to a patient. However, we could face induced infringement claims.</td>
    </tr>
    <tr>
        <td><strong>Induced Infringement (35 U.S.C. § 271(b))</strong></td>
        <td class="risk-high">HIGH</td>
        <td>If we market MUPS for hair loss and doctors administer it achieving the claimed PK parameters, we could be liable for inducing infringement of the method claims.</td>
    </tr>
    <tr>
        <td><strong>Contributory Infringement (35 U.S.C. § 271(c))</strong></td>
        <td class="risk-medium">MEDIUM</td>
        <td>MUPS has substantial non-infringing uses (hypertension), so contributory infringement is less likely but possible if marketed primarily for hair loss.</td>
    </tr>
</table>

<h3>5.2 Litigation Risk Factors</h3>

<table>
    <tr>
        <th>Factor</th>
        <th>Assessment</th>
    </tr>
    <tr>
        <td>Patent Holder Litigation History</td>
        <td>Veradermics is a well-funded company ($150M Series C). High likelihood of enforcement.</td>
    </tr>
    <tr>
        <td>Market Size</td>
        <td>Hair loss market is large (~$4B). Strong incentive to protect IP.</td>
    </tr>
    <tr>
        <td>Claim Breadth</td>
        <td>Claims are METHOD claims, not COMPOSITION claims - creates enforcement challenges but also covers more broadly.</td>
    </tr>
    <tr>
        <td>Design-Around Defensibility</td>
        <td>Strong technical arguments exist for non-infringement based on mechanism and dosage form differences.</td>
    </tr>
</table>

<hr>

<h2>Section 6: Conclusions & Recommendations</h2>

<h3>6.1 Overall Assessment</h3>

<div class="caution-box">
    <strong>BOTTOM LINE:</strong> The MUPS formulation has <span class="risk-medium">MEDIUM infringement risk</span> against US12268688B2.
    <br><br>
    <strong>Key Concerns:</strong>
    <ul>
        <li>Claims are broadly written as METHOD claims covering ANY modified release formulation</li>
        <li>Claims do not specifically limit to HPMC - they use generic "release modifier" language</li>
        <li>If MUPS achieves similar PK parameters (likely for therapeutic equivalence), literal infringement is possible</li>
        <li>Induced infringement is a significant risk if marketed for hair loss</li>
    </ul>
    <br>
    <strong>Key Defenses:</strong>
    <ul>
        <li>Specification and all examples describe HPMC matrix tablets - "release modifier" should be construed narrowly</li>
        <li>Different dosage form (capsule vs. tablet)</li>
        <li>Different release mechanism (membrane diffusion vs. gel erosion)</li>
        <li>Release modifier percentage (20-25%) below claimed range (50-80%)</li>
        <li>Can potentially design Tmax outside claimed range (>6 hours)</li>
    </ul>
</div>

<h3>6.2 Recommendations</h3>

<table>
    <tr>
        <th>Priority</th>
        <th>Action</th>
        <th>Rationale</th>
    </tr>
    <tr>
        <td><strong>1 - CRITICAL</strong></td>
        <td>Engage patent attorney for formal FTO opinion</td>
        <td>This analysis identifies risks but is not legal advice. Formal opinion needed before commercialization.</td>
    </tr>
    <tr>
        <td><strong>2 - HIGH</strong></td>
        <td>Review prosecution history (file wrapper)</td>
        <td>Identify any limiting statements made during prosecution that narrow claim scope.</td>
    </tr>
    <tr>
        <td><strong>3 - HIGH</strong></td>
        <td>Design MUPS for Tmax > 6 hours</td>
        <td>Falls outside Claim 1's "30 to 360 minutes" Tmax limitation.</td>
    </tr>
    <tr>
        <td><strong>4 - MEDIUM</strong></td>
        <td>Conduct PK study early in development</td>
        <td>Determine actual PK parameters to assess infringement risk and enable design modifications if needed.</td>
    </tr>
    <tr>
        <td><strong>5 - MEDIUM</strong></td>
        <td>Consider IPR/PGR challenge to patent</td>
        <td>If prior art exists for ethylcellulose-coated minoxidil ER formulations, patent claims may be narrowed or invalidated.</td>
    </tr>
    <tr>
        <td><strong>6 - LOW</strong></td>
        <td>Monitor for continuation applications</td>
        <td>Veradermics may file continuations with narrower claims specifically targeting MUPS-type formulations.</td>
    </tr>
</table>

<h3>6.3 Alternative Formulation Consideration</h3>

<div class="info-box">
    <strong>LOWER RISK ALTERNATIVE: Lipid Matrix Tablet</strong>
    <br><br>
    The Lipid Matrix formulation (Compritol/Precirol) may have <strong>lower infringement risk</strong> because:
    <ul>
        <li>Lipids are not "release modifiers" in the traditional polymer sense</li>
        <li>Mechanism (lipid erosion) is even more distinct from HPMC gel diffusion</li>
        <li>No hydroxyl-containing cellulose derivatives in formulation</li>
        <li>Completely different chemistry (waxy esters vs. cellulose ethers)</li>
    </ul>
    However, the broad claim language ("modified release pharmaceutical formulation") still poses some risk.
</div>

<hr>

<h2>Section 7: Claim Chart Summary</h2>

<table>
    <tr>
        <th>Claim</th>
        <th>Type</th>
        <th>Infringement Risk</th>
        <th>Best Defense</th>
    </tr>
    <tr>
        <td>1</td>
        <td>Independent</td>
        <td class="risk-medium">MEDIUM</td>
        <td>Design Tmax > 6 hours; argue "release modifier" limited to HPMC per specification</td>
    </tr>
    <tr>
        <td>2</td>
        <td>Dependent (1)</td>
        <td class="risk-medium">MEDIUM</td>
        <td>Ethylcellulose is not equivalent to HPMC "release modifier"</td>
    </tr>
    <tr>
        <td>12</td>
        <td>Dependent (2)</td>
        <td class="risk-low">LOW</td>
        <td>Our release modifier is ~20-25%, below 50-80% claimed range</td>
    </tr>
    <tr>
        <td>14</td>
        <td>Independent (4.5mg)</td>
        <td class="risk-low">LOW</td>
        <td>Our dose is 8.5mg, not 4.5mg</td>
    </tr>
    <tr>
        <td>18</td>
        <td>Independent (9mg)</td>
        <td class="risk-low">LOW</td>
        <td>Our dose is 8.5mg, not 9mg (close but not "about 9mg")</td>
    </tr>
    <tr>
        <td>24</td>
        <td>Independent (daily dose)</td>
        <td class="risk-medium">MEDIUM</td>
        <td>Design Tmax > 6 hours to fall outside PK parameters</td>
    </tr>
</table>

<hr>

<h2>Appendix: Patent Details</h2>

<p><strong>Patent Number:</strong> US 12,268,688 B2</p>
<p><strong>Title:</strong> Compositions and Methods of Use for Modified Release Minoxidil</p>
<p><strong>Assignee:</strong> Veradermics, Inc.</p>
<p><strong>Issue Date:</strong> April 8, 2025</p>
<p><strong>Priority Date:</strong> October 25, 2022 (PCT/US2023/035920)</p>
<p><strong>Expiration (estimated):</strong> October 25, 2042 (20 years from priority + potential extensions)</p>

<hr>

<p><em>This Freedom-to-Operate analysis was prepared on February 5, 2026. It is provided for informational purposes only and does not constitute legal advice. The recipient should consult with a qualified patent attorney before making any commercialization decisions.</em></p>

</body>
</html>
